A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This proof-of-concept study evaluates the clinical efficacy and safety of DCN01 in prepping of the periocular region.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Deacon Biosciences, Inc.
• Collaborator: ORA, Inc.
• Treatments: Anti-Infective Agents

Criteria

Inclusion Criteria:

• Have given a written, informed consent

• Be willing and able to follow all instructions

• A negative urine pregnancy test if female of childbearing potential

Exclusion Criteria:

• Known sensitivities to study medication or its components

• Any signs of an active infection

• Use of disallowed products during the period indicated prior to the enrollment or during the study

• Be currently pregnant, nursing, or planning a pregnancy; or be a woman that has a positive pregnancy test

• Have a condition or a situation which, in the Investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation